Related references
Note: Only part of the references are listed.Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice
Raymund R. Razonable et al.
CLINICAL TRANSPLANTATION (2019)
The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation
Camille N. Kotton et al.
TRANSPLANTATION (2018)
Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials
Per Ljungman et al.
CLINICAL INFECTIOUS DISEASES (2017)
Neutropenia in kidney and liver transplant recipients: Risk factors and outcomes
Thomas A. Mavrakanas et al.
CLINICAL TRANSPLANTATION (2017)
Transplant Infectious Diseases: A Review of the Scientific Registry of Transplant Recipients Published Data
C. N. Kotton et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2017)
Infection in Organ Transplantation
J. A. Fishman
AMERICAN JOURNAL OF TRANSPLANTATION (2017)
Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection
Robin K. Avery et al.
TRANSPLANTATION (2016)
Risk of cytomegalovirus disease in high-risk liver transplant recipients on valganciclovir prophylaxis: A systematic review and meta-analysis
Andre C. Kalil et al.
LIVER TRANSPLANTATION (2012)
The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High-Risk Kidney Transplant Recipients
A. Humar et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2010)
Extended Valganciclovir Prophylaxis in D+/R- Kidney Transplant Recipients is Associated With Long-Term Reduction in Cytomegalovirus Disease: Two-Year Results of the IMPACT Study
Atul Humar et al.
TRANSPLANTATION (2010)
Late-onset CMV disease following CMV prophylaxis
C. Donnelly et al.
IRISH JOURNAL OF MEDICAL SCIENCE (2009)
Increased Incidence of Cytomegalovirus Infection in High-Risk Liver Transplant Recipients Receiving Valganciclovir Prophylaxis Versus Ganciclovir Prophylaxis
Kevin T. Shiley et al.
LIVER TRANSPLANTATION (2009)
Oral ganciclovir versus valganciclovir for cytomegalovirus prophylaxis in high-risk liver transplant recipients
R. L. Brady et al.
TRANSPLANT INFECTIOUS DISEASE (2009)
Prophylactic Therapy With Valgancyclovir in High-Risk (Cytomegalovirus D+/R-) Liver Transplant Recipients: A Single-Center Experience
M. Montejo et al.
TRANSPLANTATION PROCEEDINGS (2009)
Delayed-onset primary cytomegalovirus disease after liver transplantation
Supha K. Arthurs et al.
LIVER TRANSPLANTATION (2007)
Experience with low-dose valganciclovir prophylaxis in adult liver transplant recipients
R. Dupuis et al.
TRANSPLANTATION PROCEEDINGS (2007)
Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients
A. Asberg et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2007)
Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
A Jain et al.
TRANSPLANTATION PROCEEDINGS (2005)
Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients
C Paya et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2004)
Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients
MD Pescovitz et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2000)
Share Paper
